According to US government website, CSL112 estimated study...

According to US government website, CSL112 estimated study completion is April 2023. Realistically, I think that the whole thing is so far off and torturously prone to failure that it would be wrong to factor in any value to it at all. It would be almost impossible to develop a treatment for millions of incredibly frail heart attack victims across many countries that would be universally accepted in a world of social media attacks and confected outrage. You only need to look at AZ vaccine to see how easily something can be shot down. More the point is the possible downside from its failure, a realisation of a $1bil+ gamble. But I'd love to wrong about this, it's still a great company. It seems that the only stocks that go up these days are ones like Afterpay that lose money.


Study Design

Go to

	Study Type:	Interventional (Clinical Trial)
1	EstimatedEnrollment:	17400 participants
2	Allocation:	Randomized
3	Intervention Model:	Parallel Assignment
4	Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
5	Primary Purpose:	Prevention
6	Official Title:	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety ofCSL112in Subjects With Acute Coronary Syndrome
7	ActualStudy Start Date:	March 21, 2018
8	EstimatedPrimary Completion Date:	July 2022
9	EstimatedStudy Completion Date:	April 2023